Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ)
CNY 16.29
(-0.12%)
CNY 16.29
(-0.12%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2.27 Billion CNY | -36.09% |
| 2022 | 3.28 Billion CNY | 67.31% |
| 2021 | 1.95 Billion CNY | 14.15% |
| 2020 | 1.7 Billion CNY | 81.92% |
| 2019 | 978.16 Million CNY | 1.34% |
| 2018 | 960.9 Million CNY | 8.19% |
| 2017 | 896.71 Million CNY | 3.39% |
| 2016 | 870.87 Million CNY | 35.62% |
| 2015 | 646.71 Million CNY | 35.58% |
| 2014 | 466.73 Million CNY | 30.76% |
| 2013 | 353.37 Million CNY | 23.4% |
| 2012 | 285.92 Million CNY | -53.17% |
| 2011 | 597.88 Million CNY | 46.31% |
| 2010 | 420.83 Million CNY | 6.57% |
| 2009 | 388.44 Million CNY | 121.78% |
| 2008 | 175.7 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 37.21 Million CNY | -91.44% |
| 2024 Q1 | 370.05 Million CNY | 296.52% |
| 2024 Q2 | 419.71 Million CNY | -17.56% |
| 2023 Q3 | 174.32 Million CNY | -63.4% |
| 2023 Q4 | -268.45 Million CNY | -253.99% |
| 2023 Q1 | 1.46 Billion CNY | 23.31% |
| 2023 Q2 | 476.32 Million CNY | -67.48% |
| 2023 FY | - CNY | -36.09% |
| 2022 Q3 | 441.76 Million CNY | -38.36% |
| 2022 Q2 | 716.65 Million CNY | 24.02% |
| 2022 Q1 | 577.85 Million CNY | 253.73% |
| 2022 Q4 | 1.18 Billion CNY | 168.9% |
| 2022 FY | - CNY | 67.31% |
| 2021 FY | - CNY | 14.15% |
| 2021 Q1 | 828.76 Million CNY | 187.41% |
| 2021 Q2 | 326.41 Million CNY | -60.61% |
| 2021 Q3 | 336.14 Million CNY | 2.98% |
| 2021 Q4 | 163.35 Million CNY | -51.4% |
| 2020 Q3 | 365.48 Million CNY | 15.09% |
| 2020 Q4 | 288.35 Million CNY | -21.1% |
| 2020 FY | - CNY | 81.92% |
| 2020 Q1 | 522.93 Million CNY | 2815.31% |
| 2020 Q2 | 317.55 Million CNY | -39.27% |
| 2019 Q3 | 152.77 Million CNY | -21.33% |
| 2019 Q1 | 346.96 Million CNY | 464.62% |
| 2019 Q2 | 194.19 Million CNY | -44.03% |
| 2019 Q4 | 17.93 Million CNY | -88.26% |
| 2019 FY | - CNY | 1.34% |
| 2018 Q3 | 130.75 Million CNY | -29.06% |
| 2018 FY | - CNY | 8.19% |
| 2018 Q1 | 346.51 Million CNY | 207.31% |
| 2018 Q2 | 184.31 Million CNY | -46.81% |
| 2018 Q4 | 61.45 Million CNY | -53.0% |
| 2017 Q1 | 260.32 Million CNY | 110.83% |
| 2017 Q3 | 128.88 Million CNY | -11.95% |
| 2017 FY | - CNY | 3.39% |
| 2017 Q4 | 112.75 Million CNY | -12.51% |
| 2017 Q2 | 146.37 Million CNY | -43.77% |
| 2016 FY | - CNY | 35.62% |
| 2016 Q1 | 215.07 Million CNY | 260.7% |
| 2016 Q2 | 153.09 Million CNY | -28.82% |
| 2016 Q3 | 148.84 Million CNY | -2.78% |
| 2016 Q4 | 123.47 Million CNY | -17.04% |
| 2015 Q1 | 160.72 Million CNY | 165.81% |
| 2015 Q4 | 59.62 Million CNY | -51.96% |
| 2015 Q3 | 124.13 Million CNY | 0.82% |
| 2015 Q2 | 123.12 Million CNY | -23.39% |
| 2015 FY | - CNY | 35.58% |
| 2014 Q4 | 60.46 Million CNY | -32.69% |
| 2014 FY | - CNY | 30.76% |
| 2014 Q2 | 132.81 Million CNY | 16.97% |
| 2014 Q1 | 113.55 Million CNY | 114.64% |
| 2014 Q3 | 89.82 Million CNY | -32.37% |
| 2013 Q4 | 52.9 Million CNY | -34.52% |
| 2013 FY | - CNY | 23.4% |
| 2013 Q1 | 69.58 Million CNY | 2.57% |
| 2013 Q2 | 110.66 Million CNY | 59.04% |
| 2013 Q3 | 80.79 Million CNY | -26.99% |
| 2012 FY | - CNY | -53.17% |
| 2012 Q1 | 112.61 Million CNY | -43.66% |
| 2012 Q2 | 54.81 Million CNY | -51.32% |
| 2012 Q3 | -7.57 Million CNY | -113.82% |
| 2012 Q4 | 67.84 Million CNY | 995.56% |
| 2011 Q1 | 90.53 Million CNY | -38.31% |
| 2011 Q2 | 128.74 Million CNY | 42.21% |
| 2011 Q3 | 139.02 Million CNY | 7.99% |
| 2011 Q4 | 199.89 Million CNY | 43.78% |
| 2011 FY | - CNY | 46.31% |
| 2010 Q3 | 93.76 Million CNY | 0.0% |
| 2010 Q4 | 146.74 Million CNY | 56.5% |
| 2010 FY | - CNY | 6.57% |
| 2009 FY | - CNY | 121.78% |
| 2008 FY | - CNY | 0.0% |